AIT Therapeutics is a mid-clinical stage biotech company that leverages their drug /device platform to deliver nitric oxide (NO) by inhalation as a potential anti-infectious agent for treating pulmonary infections, including bronchiolitis (mainly caused by respiratory syncytial virus or RSV) in infant and nontuberculous Mycobacteria (NTM) infections by Mycobacterium abscessus complex (MABSC). NO is a well-known for engaging in multiple cellular signaling and other activities. Gaseous NO is an important endogenous non-specific defense component of the innate immune response, mainly produced by macrophages via an upregulation of inducible nitric oxide synthase (iNOS). Given the endogenously supplied NO is often overcome and depleted during infection, providing gaseous NO exogenously may sustain (and even enhance) the ability to defeat invading bacteria and viruses. AITB’s treatment platform is based on delivering inhaled NO 30 minutes each time and intermittently for varying times per day for varying periods depending on different indications. The two lead products are NOxBR in bronchiolitis and NOxNTM in MABSC infection. AITB currently is conducting two clinical trials with data readouts of NOxNTM in MABSC infection Phase II study in 4Q17 and NOxBR in bronchiolitis in 1H18.